BMP.Marketing’s Post

The antipodeans Sir Ernest Rutherford "father of nuclear physics" and Sir Mark Oliphant, "Opposer of the fission bomb" were the first experimental demonstrators of nuclear fusion. Why then are the Australian Government and the Federal Opposition not working to get it developed in Australia and bring it back home? New Zealand has, so why not Australia? Interesting articles about Nuclear and I know you haven't looked at Fusion. So let's look at the nuclear or Fission option versus Fusion 1. Fission (Nuclear) Not able to be licenced. https://lnkd.in/gbm2t5uU 2. Authorities have the power to grant licenses for fusion, which is not explicitly covered by the Nuclear Act or the ARPANSA definition. https://lnkd.in/gjKFABpy The above ARPANSA link defines nuclear as fission—no mention of Fusion. 3. A fission (Nuclear)reactor without fissile fuel is a building. 4. A fusion reactor without fissile fuel is a fusion reactor building 5, Fissile (Nuclear) fuel availability and the future cost is a concern, especially for economists and users Dittmar, M. (2011). The End of Cheap Uranium. ArXiv. /abs/1106.3617 Even the UN has identified this, so why does the Fission(Nuclear) industry persist in denying its death like fossil fuels https://lnkd.in/gze5rwpr 6. Should the focus in Australia be on nuclear fission advancement or the promotion of fusion technology? 7, Fission (Nuclear) is only at present in 39 countries out of 189. 8. Is Dutton doing a Menzies and wanting a loophole to get fission (Nuclear) weapons to start with for the subs? 9. Australia still has no high-level radiation waste storage facility 10. Helion Fusion has committed to having its fusion version working in 2028 11. The FIA (Fusion Industry Association) has postulated that commercial power fusion will be available in the 2030s. 12. In its fusion conference report in 2023, the IAEA postulated that all International nuclear (Fission) Laws like the Nuclear Non-Proliferation Treaty do not consider fusion, so it seems it can be built in Australia now. 13. Fusion is also being developed "Small Modular Fusion Reactors" like Zap Energy and Avalanche Energy. 14. HB11 and the UNSW Tokamak project have positioned Australia prominently in the trillion-dollar international fusion industry. Instead of relying on fission with a limited lifetime, wouldn't it be preferable to support Australian renewables, batteries, and hydrogen energy generators and back them up with a fusion power plant? This would eliminate the traditional waste problem while still providing medical isotopes and advancements in medical technology like MRIs. Let's focus on creating a sustainable future for Australia instead of perpetuating pollution and leading to an energy crisis. https://lnkd.in/ekakyifA

⚡ Exciting developments at Nuclidium as we prepare for LSX - partnering for Life Science eXecutives! ⚡ Investments by industry giants like Lilly and BMS highlight the potential and competitive nature of the radiopharmaceutical sector. Here’s why you should meet with Leila Jaafar and Andreas Schuh on the 29th and 30th of April in London: ✅ Innovative Theranostics: Our Cu-61 and Cu-67 pairs offer precise diagnosis and targeted treatment, improving efficacy and minimizing side effects for major cancers such as breast, prostate, lung, and pancreatic. ✅ Advanced Diagnostics: Cu-61’s longer half-life and superior properties simplify manufacturing and extend usability, enhancing diagnostic applications. ✅ Effective Therapeutics: Cu-67 aligns perfectly with our targeting molecules, allowing for higher tumor dosage with reduced toxicity and shorter hospital stays. ✅ Sustainable Production: In collaboration with LinaThera, our proprietary, scalable production facilities are independent of nuclear reactors, beginning in Germany with plans for global expansion. With commitments secured and a strategic investor on board, we're gearing to close Series A2 in Q3. Join us at LSX - partnering for Life Science eXecutives to discover how our cutting-edge solutions are poised to revolutionize cancer treatment. #LSX #Radiopharmaceuticals #InvestInInnovation #LinaThera #Nuclidium

The #radiopharmaceutical field has sparked new hope for cancer patients as well as interest from investors and #pharma giants alike. The industry is seeing a surge in large pharma companies acquiring startups specializing in radiopharmaceutical development, as well as a significant increase in institutional interest in this innovative technology. With its ability to target #cancer cells directly while minimizing damage to surrounding healthy cells, radiopharmaceuticals offer an incredible opportunity to revolutionize #cancertreatment. As the technology continues to develop and investor interest grows, so does the market potential - with the sector projected to reach $39 billion by 2032. We are seeing several successful ventures like Novartis' #Pluvicto for #prostatecancer, but challenges in #manufacturing and #patientaccessibility highlight the need for a streamlined #supplychain and development processes. In a rapidly developing sector like radiopharmaceuticals, knowledge sharing to establish best practices will be the key to ensuring these life saving therapies can reach the patients who need them.

PanMediso Spotlight｜NorthStar and BWXT Medical Sign Agreement to Support Ac-225 Production The Master Services Agreement (MSA) focuses on the processing and purification of Ra-226 for the production of Ac-225. Jonathan Cirtain, President of BWXT Medical, urged that the purpose of the collaboration is to enhance the design and production of Ra-226 targets. Frank Scholz, NorthStar's CEO, highlighted the potential of the collaboration for innovative radiopharmaceutical therapies. BWXT Medical has submitted a drug master file for Ac-225 to the FDA to support clinical studies. PanMediso Holdings is committed to building a global ecosystem of industry, academia, research, diagnosis & treatment for nuclear medicine and establishing world-class preparation & production centers of medical isotope to realize the GMP-grade production and global supply of new-type isotopes, particularly Ac-225 and Ge-68, thereby bringing new power to the development of human health. #cancertherapy #Ac225 #NorthStar #BWXT #FDA #Ra226

#Radiopharmaceutical_Nuclear_Medicine Market Share Expands with Rising Demand for Targeted Cancer Treatments >> https://lnkd.in/euQS78RQ #Radiopharmaceutical/nuclear #medicine refers to a radioactive drug used for monitoring and treating #patients suffering from #cancer, heart related problems, and neural #issues. The trace amount of #radioisotope present in the medicine #binds the organic compound, which is later conveyed, to the target cell, #tissue or organ. The rays emitted by radioisotope are detected by specific #imaging device. Eckert & Ziegler SE Mallinckrodt Pharmaceuticals GE HealthCare Jubilant Life Sciences (USA) Inc. Nordion Bracco Imaging Korea Nuclear Science User Facilities (NSUF) NTP Eczacıbaşı-Monrol Nuclear Products Lantheus Medical Imaging IncLantheus MI Australia Pty Ltd Cardinal Health #healthcareindustry #pharmaceuticalindustry #healthcareresearch #biotechnology #Radiopharmaceutical #nuclearmedicine #radioactive  

PanMediso Spotlight｜Sanofi Invests Another €300 Million to Develop Next-Gen Radiopharmaceuticals On October 17, Sanofi announced a new collaboration agreement with Orano Med to accelerate the development of next-generation radioligand therapies. Under the agreement, Sanofi will make a €300 million equity investment in Orano Med, acquiring approximately 16% of the new entity, valued at €1.9 billion (about $2.055 billion). The agreement specifies that, leveraging Orano Med’s expertise and its radioligand drug pipeline, Sanofi and Orano Med will jointly focus on the discovery, design, and clinical development of alpha-particle radioligand therapies based on the lead-212 isotope. We PanMediso Holdings is committed to building a global ecosystem of industry, academia, research, diagnosis & treatment for nuclear medicine and establishing world-class preparation & production centers of medical isotope to realize the GMP-grade production and global supply of new-type isotopes, particularly Ac-225 and Ge-68, thereby bringing new power to the development of human health. #Sanofi #OranoMed #radiopharmaceuticals 

We are thrilled to announce that our VP, Medical Affairs, Kristin Schmiedehausen, MD and all authors of “The Scientific and Clinical Potentials of Imaging Cytotoxic T-Cells Using Zr-89 Crefmirlimab Berdoxam” have been awarded first place in the Educational Exhibits Section of the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting. The poster provides an overview of the currently available data and potential use cases of our investigational CD8 PET imaging agent, Zr-89 Crefmirlimab Berdoxam. Many thanks to all the collaborators who have worked with us by using our CD8 PET tracer, particularly to those who contributed to the poster.  We are elated at this news and celebrate this achievement. Read the poster here: https://lnkd.in/gpy-G3-V Learn more about CD8 Imaging in Clinical Trials by emailing info@imaginab.com #CD8ImmunoPET #immunooncology #pharma #biotech #SNMMI #radiopharmaceutical #PETCT #nuclearmedicine #theranostics #autoimmuneconditions #radiationoncology #collaborations #theranostics #radiology

CONTROVERSIAL...."if they don't have a Radiopharmaceuticals pipeline under development in their portfolio...then they can't really be considered a "big pharma" in today's market....." I found this VERY interesting when speaking with a well known and highly esteemed big pharma CMO recently..... Turn back the clock 2-3 years ago...I can vividly remember partnering with Nuclear Medicine focused Biotech companies, and speaking with Clinical Development and Medical Affairs professionals (many of which were Medical Oncologists) about why a move into the Radiopharmaceutical space could be a great move for their career! At the time (shortly after Novartis had acquired Advanced Accelerator Applications and their pipeline of radiotheranostics), this was a big ask as little was known about this potentially game changing space...with well trodden paths in the likes of ADCs, Cell Therapy, Bi Specifics, Small molecule etc well underway.... This appears to have gone FULL CIRCLE with various oncology focused drug development professionals actively looking to move into the Radiopharm space - not least encourage by the spate of recent M&A activity. Long may it continue! All of the candidates that we placed in recent years have found the experience great for their career! ARTO #nuclearmedicine #drugdevelopment #radioligand #radiotheranostic #oncology #clinicaldevelopment #medicalaffairs

PanMediso Spotlight｜Full Life's New Drug ²²⁵Ac-FL-020 Approved by the FDA On May 30, 2024, Full Life Technologies, announced that its PSMA-targeted radiopharmaceutical ²²⁵Ac-FL-020 has obtained approval from the FDA on Investigational New Drug (IND) for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Headquartered in the Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone, PanMediso Holdings is committed to building a global integration of industry, academia, research, diagnosis & treatment for nuclear medicine and establishing world-class preparation & production centers of medical isotope to realize the GMP-grade production and global supply of new-type isotopes, particularly Ac-225 and Ge-68, thereby bringing new power to the development of human health. #225Ac #PSMA #FullLife #FDA #IND #mCRPC

This $825M upfront payment deal between Arrowhead (siRNA company) and Sarepta (Biopharma) further validates the value of RNA-targeting technology. Despite siRNA has been successful in targeting Cytoplasmic RNAs, it's not potent in targeting Nuclear RNAs, which are key disease drivers in many neurodegenerative diseases. NuCyRNA Therapeutics has demonstrated robust co-targeting of both Nuclear & Cytoplasmic RNAs based on our next-gen oligo technology. We are developing 2 innovative programs in neurodegenerative diseases. DM me or email info@nucyrnatx.com to learn more! #RNA, #neurodegeneration, #ALS, #Aging